Trinity Biotech (TRIB) terminates Yorkville standby equity purchase agreement

Rhea-AI Filing Summary

Trinity Biotech plc has terminated its Standby Equity Purchase Agreement with YA II PN, LTD., an affiliate of Yorkville Advisors Global. This agreement had provided an equity line of credit facility. The company states it no longer intends to use the facility, and that ending it reflects its current financing strategy.

Insights

Capital structure and financing analyst

Trinity Biotech ends an equity line facility as part of a shift in financing strategy.

Trinity Biotech has delivered formal notice to terminate its Standby Equity Purchase Agreement with YA II PN, LTD., which provided an equity line of credit. The company explicitly notes it does not intend to make further use of this facility.

This step removes an on-call equity financing option that could have been used to raise cash through share issuance. It also means potential future dilution from drawing on this specific equity line is off the table, though no replacement funding sources are discussed in this disclosure.

The company links termination to its “current financing strategy,” indicating a deliberate capital-raising approach rather than a procedural change. Future filings and disclosures will be important to understand how Trinity Biotech plans to fund growth, manage liquidity, and support its diagnostics, biosensor, and data-center cooling initiatives.

Key Terms

Standby Equity Purchase Agreement, equity line of credit facility, forward-looking statements, safe harbor, +2 more

6 terms

Standby Equity Purchase Agreement financial

"it has formally provided notice of termination to YA II PN, LTD., ... in respect of its Standby Equity Purchase Agreement"

A standby equity purchase agreement is a contract in which an investor or group agrees to buy a company’s newly issued shares on demand, giving the company a ready source of cash it can tap when needed. Think of it like a line of credit made with stock instead of a loan: it provides financial backup but can increase the number of shares outstanding, diluting existing owners and affecting per‑share value, so investors watch these deals for their impact on ownership and earnings per share.

equity line of credit facility financial

"in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility"

An equity line of credit facility is a financing agreement that lets a company raise cash on demand by issuing new shares to a lender or investor as draws are made, similar to a credit card that’s paid by giving up a small portion of ownership instead of cash. It matters to investors because it provides flexible cash when needed but increases the number of shares outstanding, which can dilute existing ownership and affect the stock price.

forward-looking statements regulatory

"This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

safe harbor regulatory

"Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act"

Safe harbor is a rule that protects companies or individuals from legal trouble if they follow certain guidelines or procedures. It’s like having a safety net that allows them to act without fear of punishment, as long as they stick to the rules. This helps encourage honest behavior and clear standards in financial and legal activities.

Risk Factors regulatory

"and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F"

Risk factors are elements or conditions that could cause an investment's value to decrease or lead to potential losses. They are like warning signs or obstacles that can affect the success of an investment, making it uncertain or more unpredictable. Recognizing risk factors helps investors understand the possible challenges and make more informed decisions.

commercial-stage biotechnology company financial

"Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics"

A commercial-stage biotechnology company is a firm that not only develops biological medicines or technologies but has at least one product approved and actively sold, generating recurring revenue. For investors this signals a shift from speculative research to a business with sales, like a bakery that has moved from recipe testing to selling bread every day; it still carries risks from product performance, competition and pipeline development, but has clearer commercial validation.

FAQ

What did Trinity Biotech (TRIB) announce in its June 2026 Form 6-K?

Trinity Biotech announced it has terminated its Standby Equity Purchase Agreement with YA II PN, LTD., an affiliate of Yorkville Advisors Global. The agreement had provided an equity line of credit facility, which the company states it no longer intends to use as part of its financing strategy.

What is the Standby Equity Purchase Agreement Trinity Biotech terminated?

The Standby Equity Purchase Agreement was an equity line of credit facility with YA II PN, LTD., linked to Yorkville Advisors Global. It allowed Trinity Biotech to raise funds through equity issuance. The company has now provided formal notice of termination and does not plan further use of this facility.

Why did Trinity Biotech decide to terminate the Yorkville equity line facility?

Trinity Biotech states it has determined it does not intend to make any further use of the Standby Equity Purchase Agreement. Terminating the equity line of credit facility is described as reflecting the company’s current financing strategy, though no additional funding details are given here.

Does ending the SEPA change Trinity Biotech’s access to financing?

Ending the SEPA removes one specific equity line of credit facility previously available from YA II PN, LTD. The company links this decision to its current financing strategy, but this disclosure does not outline alternative facilities or capital sources it may use in the future.

What businesses does Trinity Biotech (TRIB) focus on after this financing change?

Trinity Biotech focuses on human diagnostics and diabetes management solutions, including wearable biosensors. It sells diagnostic systems for point-of-care and clinical laboratories, has acquired biosensor assets from Waveform Technologies Inc., and, via its Trinovium subsidiary, is expanding into advanced liquid cooling solutions for AI data center infrastructure.

Does Trinity Biotech provide any forward-looking statements with this announcement?

Yes. The company includes forward-looking statements about its cash position, financial resources, growth potential, market acceptance of products, recurring revenues, and results of operations. It cites numerous risks and uncertainties and invokes the safe harbor protections under the Private Securities Litigation Reform Act of 1995.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/29/2026 - 03:53 PM Accepted by SEC EDGAR 06/29/2026 - 03:53 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

TRINITY BIOTECH PLC

(Name of Registrant)

IDA Business Park

Bray, County. Wicklow, Ireland

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

This Form 6-K is being incorporated by reference into our Registration Statements on Form S-8 (File Nos. 333-182279, 333-195232 and 333-253070) and Form F-3 and (File Nos. 333-267160, 333-286020, 333-295842 and 333-280391).

EXPLANATORY NOTE

On June 29, 2026, the Company announced that it has delivered notice of termination of its Standby Equity Purchase Agreement with YA II PN, LTD., an affiliate of Yorkville Advisors Global. A copy of the press release is filed herewith as Exhibit 99.1.

EXHIBIT INDEX

Exhibit		Description
99.1		Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TRINITY BIOTECH PLC
		Trinity Biotech plc
		(Registrant)
	By:	/s/ Paul Murphy
		Paul Murphy
		Interim Chief Financial Officer

Date: June 29, 2026

Exhibit 99.1

Contact: Trinity Biotech plc Paul Murphy (353)-1-2769800	RedChip Companies Inc. Dave Gentry, CEO (1)-407-644-4256 (1)-800-RED-CHIP (733-2447) TRIB@redchip.com

Trinity Biotech Terminates Standby Equity Purchase Agreement with Yorkville

DUBLIN, Ireland (June XX, 2026) - Trinity Biotech plc (Nasdaq: TRIB), a commercial stage biotechnology company focused on human diagnostics and the development of innovative solutions addressing unmet clinical and industrial needs, today announced that it has formally provided notice of termination to YA II PN, LTD., an affiliate of financing partner Yorkville Advisors Global, in respect of its Standby Equity Purchase Agreement (the “SEPA”) for an equity line of credit facility.

The Company has determined that it does not intend to make any further use of the SEPA. Accordingly, termination of the equity line of credit facility reflects the Company’s current financing strategy.

Forward-Looking Statements

This release includes statements that constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”), including but not limited to statements related to Trinity Biotech’s cash position, financial resources and potential for future growth, market acceptance and penetration of new or planned product offerings, and future recurring revenues and results of operations. Trinity Biotech claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. These forward-looking statements are often characterized by the terms “may,” “believes,” “projects,” “expects,” “anticipates,” or words of similar import, and do not reflect historical facts. Specific forward-looking statements contained in this release may be affected by risks and uncertainties, including, but not limited to, our ability to capitalize on the Waveform transaction and our recent acquisitions, our continued listing on the Nasdaq Stock Market, our ability to achieve profitable operations in the future, our ability to successfully develop and commercialize data center cooling & thermal management solutions for AI and high-performance computing, the impact of the spread of COVID-19 and its variants, the possible pause and/or disruption in U.S. Government funding for HIV tests produced by Trinity Biotech, potential excess inventory levels and inventory imbalances at the Company’s distributors, losses or system failures with respect to Trinity Biotech’s facilities or manufacturing operations, the effect of exchange rate fluctuations on international operations, fluctuations in quarterly operating results, dependence on suppliers, the market acceptance of Trinity Biotech’s products and services, the continuing development of its products, required government approvals, risks associated with manufacturing and distributing its products on a commercial scale free of defects, risks related to the introduction of new instruments manufactured by third parties, risks associated with competing in the human diagnostic market, risks related to the protection of Trinity Biotech’s intellectual property or claims of infringement of intellectual property asserted by third parties, and risks related to the condition of the United States economy and other risks detailed under “Risk Factors” in Trinity Biotech’s annual report on Form 20-F for the fiscal year ended December 31, 2025 and Trinity Biotech’s other periodic reports filed from time to time with the United States Securities and Exchange Commission. Forward-looking statements speak only as of the date the statements were made. Trinity Biotech does not undertake and specifically disclaims any obligation to update any forward-looking statements.

About Trinity Biotech

Trinity Biotech plc (NASDAQ: TRIB) is a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The Company develops, acquires, manufactures, and markets diagnostic systems for the point-of-care and clinical laboratory segments of the diagnostic market and has recently entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc. Through its Trinovium subsidiary, Trinity Biotech is extending its fluid manufacturing and analytical capabilities into advanced liquid cooling solutions for AI data center infrastructure. Trinity Biotech sells directly in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. For further information, please visit www.trinitybiotech.com.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-991 EXHIBIT 99.1 9.5 KB